Local manufacturing for local supply
Strengthening healthcare systems through regional expertise and global scale
Healthcare systems around the world depend on consistent, reliable access to essential medicines. Local for local means producing essential medicines close to the markets and patients they serve. This approach can help reduce supply risks, improve responsiveness to regional demand and strengthen continuity of supply for healthcare systems.
Building resilient medicine supply in a changing world
Modern healthcare depends on complex supply networks that span countries and continents. Hospitals, healthcare professionals and patients require access to esssential medicines; shortages and supply interruptions can have significant consequences.
At the same time, healthcare systems face growing pressure. Ongoing supply chain disruptions, growing demand, demographic change and geopolitical uncertainty continue to challenge the availability of critical healthcare products like antibiotics, oncology treatments, critical care medicines and intravenous fluids.
These challenges have highlighted the importance of resilient supply chains and regional manufacturing capacity. Healthcare systems increasingly seek partners that can combine local production, regional expertise and operational flexibility to help maintain access to essential products when they are needed most.
Why local for local matters
Resilient healthcare begins with strong local foundations for critical products used in hospitals every day. That is why our local-for-local approach focuses on producing essential medicines close to the markets they serve, to help reduce supply risks, support healthcare system stability and improve responsiveness to regional demand. Regional operations are supported by a broader global network that provides additional expertise, manufacturing capabilities and supply flexibility.
This balance between local presence and global reach helps strengthen continuity of supply for essential medinices and supports long-term healthcare security. Fresenius continues to invest in manufacturing, logistics, research and innovation capabilities that help healthcare providers access essential medicines.
~70%
of Fresenius Kabi medicines sold in the United States are produced domestically1
~99%
of Fresenius Kabi products sold in Europe are produced in Europe2
Our local-for-local approach in action
Regional manufacturing networks
Our manufacturing facilities, research centers, distribution hubs, and commercial operations are located across major regions worldwide. These capabilities allow critical products like antibiotics and IV fluids to be developed and manufactured closer to the patients and healthcare providers they serve.
Flexible and resilient supply chains
The local-for-local model is strengthened by access to a diversified global manufacturing and supply network. This combination of regional production and global connectivity helps provide flexibility and continuity during periods of increased demand or supply disruption.
Investment in healthcare infrastructure
We continue to invest in manufacturing modernization, capacity expansion, research and development, and logistics networks. These investments help strengthen healthcare supply, support innovation and prepare for future patient needs.
A long-term commitment to healthcare
Through investments, regional manufacturing capabilities and continued innovation, Fresenius remains focused on providing essential medicines, helping healthcare systems build resilience and meeting the evolving needs of patients today and in the future.
References
1. Fresenius. Fresenius SE - Equity Story Briefing Deck. https://www.fresenius.com/sites/default/files/2026-03/fresenius_se_equity_story_briefing_deck_fy25_final.pdf
2. Data on file, Fresenius Kabi 2026